Every 10-Q that Precipio, Inc. (PRPO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRPO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRPO filings page.
Precipio, Inc. reported higher net sales and case volumes for the quarter and six months ended June 30, 2026, but remains unprofitable and subject to substantial doubt about its ability to continue as a going concern. Net sales for the quarter rose to $7.0 million, up 24% year over year, driven by a 26% increase in diagnostic cases to 4,652 and stronger product revenue. For the first half of 2026, net sales were $13.7 million, up 30%, with cases up 42% to 9,564.
Gross profit improved to $3.1 million for the quarter and $5.9 million year to date, with gross margins of 45% and 43%, respectively. Operating expenses increased, including a $0.9 million rise in stock-based compensation over six months, leading to an operating loss of $2.0 million and a net loss of $1.7 million for the first half. Operating cash flow was positive at $0.7 million, supported by $0.4 million of non-recurring Employee Retention Credit receipts. As of June 30, 2026, the company held $3.1 million in cash, working capital of $2.8 million, total assets of $21.3 million, and an accumulated deficit of $104.5 million. Management states that continued operations over the next twelve months depend on executing the business plan, generating additional revenue, and obtaining financing as needed, and explicitly notes substantial doubt about the company’s ability to continue as a going concern.
Precipio, Inc. reported sharply higher activity but continued losses for the three months ended March 31, 2026. Net sales rose to $6.7M from $4.9M, driven by service revenue, as cases processed increased to 4,912 from 3,021. Gross profit improved to $2.7M, though gross margin dipped to 41% from 43% due to lower average price per case.
The company recorded a net loss of $1.4M versus $0.9M a year earlier, with higher operating expenses including $1.0M of stock-based compensation. Cash was $2.6M and working capital $2.1M, with slightly positive operating cash flow of $0.1M. Management states there is substantial doubt about Precipio’s ability to continue as a going concern without additional revenue growth or financing.
Precipio, Inc. (PRPO) reported Q3 2025 results. Net sales were $6,767 thousand, up from $5,209 thousand a year ago, driven by higher diagnostic testing revenue from Medicare and third-party payers. Gross profit rose to $3,005 thousand. Operating loss narrowed to $61 thousand and net loss improved to $79 thousand from $626 thousand.
For the nine months, net sales were $17,350 thousand versus $13,082 thousand, with net loss improving to $889 thousand from $3,925 thousand. Cash at quarter-end was $2,305 thousand, aided by $1,260 thousand of warrant exercise proceeds and $319 thousand provided by operating activities. The company disclosed “substantial doubt” about its ability to continue as a going concern over the next twelve months. As of November 11, 2025, common shares outstanding were 1,752,007.
Precipio, Inc. reported net sales of $5.65 million for the three months ended June 30, 2025, up from $4.44 million a year earlier, led by service revenue of $5.005 million versus $3.909 million. Gross profit for the quarter was $2.43 million compared with $1.72 million in the prior year. The company recorded net income of $74 thousand in the quarter versus a $1.22 million loss in Q2 2024; for the six months it reported a net loss of $810 thousand compared with a $3.30 million loss a year earlier. A material contributor to quarterly other income was a recorded Employee Retention Credit of approximately $789 thousand.
The balance sheet shows total assets of $18.82 million, cash of $1.13 million and an accumulated deficit of $103.3 million. Management discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months absent additional revenue or financing. Material items disclosed include purchase commitments of approximately $2.2 million, a CHC temporary funding balance of about $0.6 million to be repaid through January 2026, and customer concentration with one customer representing ~27% of net sales.